Lentiviral vectors for treating and modeling human CNS disorders.
Vectors based on lentiviruses efficiently deliver genes into many different types of primary neurons from a broad range of species including man and the resulting gene expression is long term. These vectors are opening up new approaches for the treatment of neurological diseases such as Parkinson's disease (PD), Huntington's disease (HD), and motor neuron diseases (MNDs). Numerous animal studies have now been undertaken with these vectors and correction of disease models has been obtained. Lentiviral vectors also provide a new strategy for in vivo modeling of human diseases; for example, the lentiviral-mediated overexpression of mutated human alpha-synuclein or huntingtin genes in basal ganglia induces neuronal pathology in animals resembling PD and HD in man. These vectors have been refined to a very high level and can be produced safely for the clinic. This review will describe the general features of lentiviral vectors with particular emphasis on vectors derived from the non-primate lentivirus, equine infectious anemia virus (EIAV). It will then describe some key examples of genetic correction and generation of genetic animal models of neurological diseases. The prospects for clinical application of lentiviral vectors for the treatment of PD and MNDs will also be outlined.
Azzouz
Mimoun
M
Oxford BioMedica (UK) Ltd, The Oxford Science Park, Medawar Center, Oxford OX4 4GA, UK. m.azzouz@oxfordbiomedica.co.uk
Kingsman
Susan M
SM
Mazarakis
Nicholas D
ND
D000818:Animals; D002493:Central Nervous System Diseases / Q000628:therapy*; D004195:Disease Models, Animal; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D006816:Huntington Disease / Q000628:therapy; D016086:Lentivirus / Q000235:genetics*; D016472:Motor Neuron Disease / Q000628:therapy; D010300:Parkinson Disease / Q000628:therapy